Zhang Junhua, Zhang Yichao
The Second Department of Cardiology, Lacey People's Hospital Laixi, Qingdao, China.
Am J Transl Res. 2021 Aug 15;13(8):9796-9801. eCollection 2021.
To explore the clinical effects of the intra-aortic balloon pump (IABP) combined with tirofiban in the treatment of acute myocardial infarction (AMI) and to analyze the combination's influence on patient serum levels.
106 patients with AMI admitted to our hospital from February 2017 to February 2018 were recruited as the research cohort. The patients were randomly placed into a control group and an experimental group according to their order of admission, with 53 patients in each group. The patients in the control group were treated with IABP, while the experimental group was treated with IABP combined with tirofiban. The two groups' clinical efficacy and serum levels were compared.
The clinical efficacy in the experimental group was significantly higher than the clinical efficacy in the control group. After the treatment, both groups' serum indexes were significantly better, and the experimental group's indexes were comparatively better than the control group's indexes. The experimental group's thrombolysis and thrombin myocardial infarction (TIMI) glow grades were much better than the glow grades in the control group. The experimental group's left ventricular ejection fraction (LVEF) index was higher than the control group', while the left ventricular end-diastolic dimension (LVEDD) index and the left ventricular end-systolic dimension (LVESD) index in the experimental group exhibited lower levels when compared to the control group. The hemorheological parameters in the experimental group were much lower than the hemorheological parameters in the control group, and the difference between the two groups was statistically significant (P < 0.05).
The clinical effects of an IABP pump combined with tirofiban in treating AMI are significant. The patients' clinical symptoms were alleviated drastically, and their serum levels and cardiac and cardiovascular functions improved significantly. Therefore IABP combined with tirofiban in the treatment of AMI is worthy of clinical application and promotion.
探讨主动脉内球囊反搏（IABP）联合替罗非班治疗急性心肌梗死（AMI）的临床效果，并分析该联合治疗对患者血清水平的影响。
选取2017年2月至2018年2月我院收治的106例AMI患者作为研究队列。根据患者入院顺序将其随机分为对照组和实验组，每组53例。对照组患者接受IABP治疗，实验组患者接受IABP联合替罗非班治疗。比较两组的临床疗效和血清水平。
实验组的临床疗效显著高于对照组。治疗后，两组的血清指标均显著改善，且实验组的指标相对优于对照组。实验组的溶栓及心肌梗死溶栓（TIMI）血流分级明显优于对照组。实验组的左心室射血分数（LVEF）指标高于对照组，而实验组的左心室舒张末期内径（LVEDD）指标和左心室收缩末期内径（LVESD）指标低于对照组。实验组的血液流变学参数远低于对照组，两组差异具有统计学意义（P < 0.05）。
IABP联合替罗非班治疗AMI的临床效果显著。患者的临床症状得到明显缓解，血清水平以及心脏和心血管功能显著改善。因此，IABP联合替罗非班治疗AMI值得临床应用和推广。
